EANS-Adhoc: LifeWatch receives CE mark for its LifeWatch V health smart phone (with document)

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Justice/Processes/New Products/LifeWatch AG
06.12.2012

Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss
Exchange: LIFE), the leading wireless remote cardiac and medical
patient monitoring service provider in the U.S., today reports that
its LifeWatch V health smartphone platform was awarded the CE Mark
(Number 2074225CE02). The CE Mark allows LifeWatch AG to launch its
new LifeWatch V in Europe.

You will find a PDF-version of this press release at the end of this
message.

A CE mark confirms that the LifeWatch V system has met the applicable
directives of the European Commission (EC) and as such, can be
marketed to the 30-nation EEA and Switzerland. The LifeWatch V is a
fully featured state-of-the-art smartphone that allows patients and
health- and wellbeing-conscious consumers to self-operate a wide
range of embedded medical sensors, wellness-related applications,
cloud-based services and 24/7 call center support.

By using the barely visible sensors on the phone's frame, patients
and health- and wellness consumers can track, capture, collect and
analyze their health measurements anywhere anytime. The sensors
include ECG, body temperature, blood glucose, heart rate, blood
oxygen saturation, body fat percentage and stress analysis
measurement. All of the collected data can be retrieved from the
cloud for a follow-up. Users can take corrective action, plan diets
and activities, securely share the information with a health provider
or family member, trend and analyze the data and more. Patients may
also program the LifeWatch V to remind them of their drug type, dose
and intake time.

The LifeWatch V handset unit includes a service enablement platform
to support the transmission of medical data to be analyzed, evaluated
and communicated to health professionals and call center personnel
around the clock. The device wirelessly interacts with a cloud-based
environment allowing its' users direct access to a wide range of
complementary medical and wellness related services.

The LifeWatch V smartphone is an important milestone on the Company's
way towards more diversification into new service areas such as the
consumer and wellness markets and into new geographies.

"This is the first time in the company's history that a
multi-parameter device with five medical functions has been awarded
the CE Mark", stated Dr. Yacov Geva, Chairman of LifeWatch AG. "The
approval demonstrates our capacity to develop and manufacture devices
that meet commercial regulatory requirements not only in the U.S. but
also in Europe and elsewhere".

LifeWatch is currently in discussions with a number of multi-national
cell carriers, pharmaceutical and healthcare providers all over the
world on partnership opportunities of the LifeWatch V.

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare
technology and solution company, specializing in advanced telehealth
systems and wireless remote patient monitoring services. LifeWatch
services cater to individuals, ranging from high-risk and chronically
ill patients, to consumers of health and wellness products. LifeWatch
AG has operative subsidiaries in the United States, in Switzerland
and in Israel and is the parent company of LifeWatch Services Inc.,
and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a
leading US-based provider of cardiac monitoring services and home
sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch
Technologies Ltd., based in Israel, is a leading developer and
manufacturer of telemedicine products. The Company is planning to
introduce the LifeWatch V, an Android-based smartphone with medical
sensors and apps that uses a cloud-based service platform. For
additional information, please visit {www.lifewatch.com}[HYPERLINK:
http://www.lifewatch.com].

Sign-up for customized email alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify
forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and
projections about future events and financial trends that it believes
may affect the financial condition, results of operations, business
strategy, short term and long term business operations and
objectives, and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. In light
of these risks, uncertainties and assumptions, the forward-looking
events and circumstances described may not occur and actual results
could differ materially and adversely from those anticipated or
implied in the forward-looking statements. All forward-looking
statements are based only on data available to LifeWatch AG at the
time of the issue of this press release. LifeWatch AG does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/fwg66J4J

Further inquiry note:
Sensus Communication Consultants, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

end of announcement euro adhoc
--------------------------------------------------------------------------------

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/fwg66J4J

issuer: LifeWatch AG
Rundbuckstrasse 6
CH-8212 Neuhausen am Rheinfall
phone: +41 52 632 00 50
FAX: +41 52 632 00 51
mail: users@lifewatch.com
WWW: www.lifewatch.com
sector: Healthcare Providers
ISIN: CH0012815459
indexes: SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
SIX Swiss Exchange
language: English